{
  "id": 3527491,
  "title": "Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial",
  "url": "https://urgent.news/2026/08/26/zepbound-may-cut-healthcare-costs-study-says-summit-akeso-drug-hits",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-26T14:11:35.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/zepbound-costs-ivonescimab-mckesson-sentivera-imaavy-bausch/828680/"
  },
  "original_language": "en",
  "account": null,
  "summary": "A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Akeso, Summit hail ivonescimab's biliary tract cancer win in China-only Phase 3 trial",
        "url": "https://urgent.news/2026/08/26/akeso-summit-hail-ivonescimabs-biliary-tract-cancer-win-in-china-only",
        "published": "2026-08-26T11:02:44.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}